// App-Quantinova.ai

FRI0179 : COMPARISON OF TOCILIZUMAB AS MONOTHERAPY OR IN COMBINATION WITH NON-BIOLOGICAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS) IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) AND AN INADEQUATE RESPONSE TO ANTI-TNF AGENTS

Researchers

Presenter

  • A. Ostor

Principal Investigators

  • J.A. Roman Ivorra

  • J. Wollenhaupt

  • C. Mpofu

  • C. Bernasconi

  • J. Sibilia

  • V. Bykerk

Medical Centers

  • Mount Sinai Hospital, Toronto, ON, Canada

  • Schon-Klinik, Hamburg, Germany,

  • Hopital Hautepierre, Strasbourg, France

  • Hospital Universitario La Fe de Valencia, Valencia, Spain

  • University of Cambridge, Cambridge, United Kingdom

  • Hosp Spec Surg, New York, United States

Locations

  • Canada

  • Germany

  • Spain

  • United Kingdom

  • United States

  • France

Companies

  • F. Hoffmann-La Roche

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • Alanine transaminase

  • Aspartate aminotransferase

Drug/Treatment

  • Hydroxychloroquine

  • sulphasalazine

  • Methotrexate

  • Tocilizumab

  • HWA-486

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved